Sign in
CompletedNo phase

rTMS as Add on Treatment for Substance Use Disorders

Key facts

Who runs it
Yale University
Where
Hartford, United StatesSee the site
Trial code
Status
Completed
People taking part
47 people enrolled
Started
12 May 2025
Ended
24 Nov 2025
Type of study
Interventional, 2 groups
Treatments tested
  • repetitive transcranial magnetic stimulation (rTMS) for AUD
  • repetitive transcranial magnetic stimulation (rTMS) for OUD
Record updated
29 September 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Be able to give valid informed consent in English
  • Absence of cognitive impairment: IQ equivalent of ≥ 70 on the WRAT
  • Receiving treatment for either AUD or OUD

Who cannot take part

  • History of any neurological disorder that would increase seizure risk from rTMS such as stroke, brain lesions, previous neurosurgery, any history of seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than one month
  • Use of benzodiazepines in the last 48 hours prior to rTMS. Benzodiazepines are used during alcohol withdrawal management but then are discontinued prior to recruitment into the study. Therefore, rTMS eligible participants will not continue taking benzodiazepines
  • First-degree family history of epilepsy or multiple sclerosis
  • Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps or sensors, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object in the body that precludes rTMS administration
  • Lifetime history of schizophrenia, bipolar disorder, mania
  • History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke, or transient ischemic attack
  • Current meeting withdrawal criteria for alcohol: AUD participants will not meet for clinically significant alcohol withdrawal: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) ≤ 5
  • Current use of anti- or pro-convulsive action
  • Pregnant or lactating women
  • TMS contraindications
  • Treatment center discharge date does not allow for scheduling of all 5 rTMS days

Where in United States

  • Hartford HealthcareHartford, United States

About the trial

What the trial wants to find out

This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD).

Read full original descriptionShow less

The critical questions this study seeks to answer are: which rTMS type applied to l-dlPFC in OUD participants will induce the greatest reduction of opioid use post-treatment? Is inhibitory rTMS applied to medial prefrontal cortex (mPFC) more effective than excitatory rTMS applied to l-dlPFC at reducing alcohol use post treatment in AUD participants?

The 2 groups in the trial

  • AUDTreatment being tested

    Individuals receiving treatment from HHC for AUD. Participants will be asked to complete a battery of tasks at the prior to the first rTMS session and after the last rTMS session. Each rTMS eligible participant will be scheduled for 5 rTMS visits (to be completed within 2 weeks from start to finish). Each rTMS session will start with finding motor hotspot, the rTMS dose, then application of rTMS. Within AUD participants, random assignment of rTMS site (cTBS at mPFC vs iTBS at l-dlPFC) will occur in sets of 6 thus increasing rTMS site distribution even if a small sample is collected.

    Treatment: repetitive transcranial magnetic stimulation (rTMS) for AUD

  • OUDTreatment being tested

    Individuals receiving treatment from HHC for OUD. Participants will be asked to complete a battery of tasks at the prior to the first rTMS session and after the last rTMS session. Each rTMS eligible participant will be scheduled for 5 rTMS visits (to be completed within 2 weeks from start to finish). Each rTMS session will start with finding motor hotspot, the rTMS dose, then application of rTMS. Within OUD participants, random assignment of rTMS type (cTBS vs iTBS ) applied to l-dlPFC will occur in sets of 6 thus increasing rTMS site distribution even if a small sample is collected.

    Treatment: repetitive transcranial magnetic stimulation (rTMS) for OUD

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
29 September 2026